| HS Code | 605937 |
| Product Name | Mahuang Yuxingcao Powder Veterinary Grade API |
| Chinese Name | 麻黄鱼腥草散 |
| English Name | Ephedra and Houttuynia Powder |
| Product Type | Herbal veterinary active pharmaceutical ingredient |
| Grade | Veterinary Grade |
| Active Ingredients | Ephedrine, pseudoephedrine, houttuynine, flavonoids, volatile oils |
| Botanical Sources | Ephedra sinica Stapf and Houttuynia cordata Thunb. |
| Pharmacological Actions | Antibacterial, anti-inflammatory, antiviral, antipyretic, antitussive, antiasthmatic, immunomodulatory |
| Indications | Respiratory diseases in livestock and poultry, including cough, asthma, bronchitis, pneumonia, and heat-clearing detoxification |
| Target Animals | Swine, poultry, cattle, sheep, goats, dogs, cats, and other veterinary species |
| Dosage Forms | Tablets, injections, capsules, powders, granules, premix, solutions |
| Administration Route | Oral, injection, premix, drinking water, or as directed by a veterinarian |
| Appearance | Brown to yellowish-brown fine powder |
| Specification | Customizable, e.g., 10:1, 20:1, 50:1 extract ratio or standardized to marker compounds |
| Packaging | 25 kg fiber drum, 1 kg foil bag, or customized packaging |
| Storage | Cool, dry, well-ventilated place, away from moisture and direct sunlight |
| Shelf Life | 24 months in unopened original packaging |
| Quality Standard | Complies with veterinary pharmacopoeia or enterprise standard |
| Certification | GMP, ISO, or veterinary drug approval as applicable |
| Origin | China |
As an accredited Mahuang Yuxingcao Powder Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | Mahuang Yuxingcao Powder Veterinary Grade API: 25 kg sealed fiber drums with double polyethylene liners, suitable for tablets, injections, capsules, powders. |
| Container Loading (20′ FCL) | 20′ FCL: Mahuang Yuxingcao Powder Veterinary Grade API, palletized/drummed, securely stowed in dry container, protected from moisture, contamination, and temperature extremes. |
| Shipping | Mahuang Yuxingcao Powder Veterinary Grade API is shipped in sealed, moisture-proof, light-resistant containers, clearly labeled with batch, expiry, and hazard data. Transport at controlled ambient temperature, avoiding excessive heat, moisture, and contamination. Packed to prevent leakage, complying with veterinary API and dangerous goods regulations, with documentation and MSDS included. |
| Storage | Store Mahuang Yuxingcao Powder Veterinary Grade API in a cool, dry, well-ventilated area, away from direct sunlight, heat, moisture, and incompatible materials. Keep containers tightly closed, labeled, and off the floor. Protect from contamination, pests, and unauthorized access. Maintain recommended temperature (15–25°C) and humidity. Use first-in, first-out. Do not store near feed, food, or veterinary drugs. |
| Shelf Life | Veterinary-grade: typically up to 24 months when stored sealed in original packaging, cool, dry, protected from light, moisture, and contamination. |
In high-density broiler barns where water medication is delivered through proportioner pumps, the powder is blended with a carrier system consisting of anhydrous dextrose, citric acid, and sodium chloride before filling into sachets or tubs for farm-side reconstitution. The API powder contains both water-soluble ephedrine alkaloid salts and fibrous insoluble particles from Ephedra sinica and Houttuynia cordata herb material; the soluble fraction is pH-dependent. At pH 5.5 or below, ephedrine alkaloids remain protonated and dissolved, whereas flavonoid-bearing particles from Houttuynia cordata require continuous agitation to remain suspended. For proportioner stock solutions prepared at 1:100 or 1:200, xanthan gum at 0.02–0.10 g/100 mL prevents nozzle clogging and reduces diaphragm valve wear. Blending is carried out in a ribbon blender at 60–70% fill for 15 min after all ingredients are charged; active marker assay across 10 sampling points should show a coefficient of variation not exceeding 5.0%. Screening through a 0.250 mm sieve removes fiber bundles that would otherwise obstruct dosing pump diaphragms. Stock solutions are consumed within 24 h under high-temperature barn conditions because non-sterile waterlines support bacterial growth; short-duration medication programs rely on citric acid at 0.10–0.30 g/100 mL rather than preservative systems. Settling tests under static conditions should show less than 2.0 mm sediment after 6 h, and the solution is filtered through a 125 µm inline screen at the proportioner inlet to protect the pump check valves.
Terminal sterilization of Mahuang Yuxingcao injectable solutions is constrained by the thermolability of houttuynin and the steam volatility of ephedrine alkaloids when decoction is performed in open vessels. A closed-jacketed extraction vessel maintained at 90–95°C reduces volatile oil loss, but the resulting aqueous decoction contains colloids, high-molecular-weight polysaccharides, and bacterial lipopolysaccharides. Centrifugation at 12,000 × g for 15 min removes gross particulates; subsequent ultrafiltration through a 10 kDa MWCO polyethersulfone membrane reduces endotoxin burden while allowing ephedrine and flavonoid markers to pass into the permeate. The permeate is adjusted to pH 4.5–5.5 with citric acid, made isotonic with sodium chloride at 9.0 g/L, and passed through a 0.22 µm sterilizing-grade filter. Published membrane loading data for this specific herbal decoction configuration is limited; filters should therefore be integrity-tested before and after each batch to identify premature fouling from pectin or phenolic-protein complexes. If a terminal sterilization cycle is selected, steam sterilization at 121°C for 15 min may produce a loss of houttuynin marker and shift the characteristic odor; an F0 value of at least 8 must be validated by challenge studies in the target formulation. Multidose vials require antimicrobial preservation unless the product is registered as single-dose; preservative selection is restricted by the potential for benzyl alcohol to precipitate with herbal colloids. The final aqueous injection is filled into amber glass vials and stored below 25°C because light accelerates oxidative browning of flavonoid fractions.
| Quality attribute | Measurement standard / test method |
|---|---|
| Sterility | USP <71>, Ph. Eur. 2.6.1 |
| Bacterial endotoxin | USP <85>, Ph. Eur. 2.6.14 |
| Particulate matter in injections | USP <788>, Ph. Eur. 2.9.19 |
Capsule filling of this API requires blending not merely for assay but for flow; the untreated herbal powder tends to cake at relative humidity above 60% because Houttuynia cordata powder contains hygroscopic polysaccharides and saponins. On a dosator-type capsule filling machine, a preblend containing 30% API and 70% spray-dried lactose monohydrate, with 0.5% colloidal silicon dioxide and 1.0% magnesium stearate, maintains a Hausner ratio below 1.25. Size 3 HPMC capsules at fill weights from 180 mg to 240 mg are filled at speeds up to 30,000 capsules/h without ejection force spikes, provided the powder bed relative humidity is held below 45%. The magnesium stearate level must remain at or below 1.0% to avoid retarding dissolution of the alkaloid fraction in gastric pH; content uniformity testing follows USP <905> with acceptance value not exceeding 15.0% for herbal veterinary specifications. Capsule shells are desiccant-sealed because residual moisture in the API above 5.0% causes shell brittleness and delayed dissolution; a 2 g silica gel canister per 100 mL HDPE bottle is typical for finished packed capsules. For cats and small dogs, the filled capsule unit is often opened and the contents dispersed in feed, which requires that the blend remain free-flowing at ambient humidity during use.
Carrier particle size distribution and dusting potential in swine premixes determine whether the active marker remains attached to the carrier during auger conveying, bucket elevators, and drop-through mixers. A solvent-extracted soybean meal carrier with a geometric mean particle diameter between 450 µm and 800 µm provides enough surface roughness to retain fine API particles, while a calcium carbonate carrier below 150 µm increases dusting and electrostatic separation. The API powder is first dispersed onto 0.5 g/100 g soybean oil in a paddle mixer at low shear for 120 s to reduce electrostatic charge, then combined with the main carrier and mixed for 15 min in a double-ribbon mixer at 60% fill. The resulting premix is sampled according to ISO 6497:2002 at the mixer discharge, and active marker recovery is measured by liquid chromatography. Coefficient of variation above 5.0% at the point of use indicates segregation during conveying; corrective actions include reducing carrier particle size range mismatch to less than 1:3, adding 0.3 g/100 g calcium stearate, or shortening pneumatic conveying distance. The final premix is packed in 25 kg bags with a polyethylene liner and stored below 30°C and 60% RH; caking under high humidity reduces flow through feed mill micro-additive dosing systems and causes assay error at the mixer outlet.
Because the material’s angle of repose commonly exceeds 40° and its compressibility is inadequate for direct compression at API loads above 20%, dry granulation is employed for tablets intended for companion animals and swine. A formulation containing 15.0% API, 45.0% microcrystalline cellulose PH102, 30.0% lactose monohydrate, 4.0% croscarmellose sodium, 0.5% colloidal silicon dioxide, and 0.5% magnesium stearate is compacted on a roller compactor at roll force between 10 kN/cm and 20 kN/cm, then screened to granules of 0.8–1.4 mm. Direct compression is acceptable only for low-dose tablets where API content does not exceed 5.0% and residual moisture is below 5.0%; in such cases, a rotary tablet press operating at 50–80 kN with 9 mm flat-faced bevel-edge tooling produces tablets with hardness of 60–100 N and friability below 1.0%. Disintegration time in 0.1 N HCl at 37°C is expected to be under 30 min for uncoated tablets; film coating with an aqueous HPMC system at 3.0% weight gain can delay disintegration to 45 min but improves palatability masking in dogs. Ephedrine content uniformity is assessed by HPLC using a C18 column with UV detection at 210 nm, with a specification of 90.0–110.0% of label claim for each individual tablet.
When the API pre-blend is used in drinking water solutions without further granulation, the dissolution and suspension behavior of the native herbal particles controls dose delivery more than the active marker assay in the dry powder. A stock solution is prepared at 1:100 or 1:200 in a dedicated mixing tank, using water at 20–25°C with vigorous recirculation; the pH is adjusted to 4.0–4.5 with citric acid to protonate ephedrine alkaloids and improve their dissolution from the powder matrix. Sodium benzoate at 0.10 g/100 mL and potassium sorbate at 0.10 g/100 mL are added when the stock solution is held beyond 12 h, but these preservatives are unnecessary for short-duration administration. Inline filtration through a 125 µm stainless-steel screen protects proportioner pistons from insoluble fiber fragments; coarse particles larger than 250 µm must be removed from the API by air-jet sieving before the pre-blend is packaged. Oxidation of methyl nonyl ketone from Houttuynia cordata is slowed by 0.05 g/100 mL sodium metabisulfite when the solution is prepared, but the same additive should not be combined with chlorinated disinfectants used in waterline cleaning. The proportioner diaphragm wear rate increases when suspended solids exceed 0.5% v/v; a settling test under static conditions should show less than 2.0 mm sediment after 6 h for a viable proportioner feed. Stock solution pH above 6.0 produces visible precipitation of alkaloid-herb fiber complexes and should be rejected for medication use.
High-shear wet granulation shifts the 5.0% moisture boundary for herbal granules because the binder solution wets the porous fiber matrix and requires a drying endpoint below 5.0% residual moisture to prevent mold growth and caking. A 300 L vertical high-shear mixer with an impeller speed of 120 rpm and a chopper speed of 1,500 rpm is charged with the API powder, 3.0–5.0 g/100 g povidone K30 as binder, and 10.0–20.0 g/100 g pregelatinized starch; water is added at 8.0–12.0 g/100 g while monitoring power draw. The endpoint is reached when the current draw plateaus or the torque value increases by 20–30% above dry-mix baseline; overgranulation produces hard granules that survive sieving but fail to disintegrate in the stomach. The wet mass is milled through a 4.0 mm screen, dried in a fluid-bed dryer with inlet air at 60–65°C and product temperature not exceeding 40°C, then sieved to retain 20–60 mesh. Granules above 20 mesh are re-milled, while fines below 60 mesh are recycled into the next granulation at up to 20% of the API charge. Final granules are filled into aluminum-foil-lined sachets and stored below 30°C and 60% RH; the moisture specification is 3.0–5.0%, water activity below 0.60, and bulk density between 0.45 g/mL and 0.65 g/mL to ensure consistent dosing scoops in farm use.
For neonatal calves and lambs, a concentrated oral drench is prepared by dispersing the granular intermediate in a vehicle of 1.2-propanediol, citric acid, and xanthan gum. The drench is filled into sealed polyethylene dosing syringes at 10 mL or 20 mL volume, with sodium benzoate at 0.10 g/100 mL to inhibit yeast growth if the product is ambient-stored under farm conditions. The suspension rheology is non-Newtonian with a yield stress between 2.0 Pa and 6.0 Pa, which prevents settling during 12 months of shelf life yet still allows passage through a 2.0 mm oral dosing nozzle. The pH is maintained at 4.0–4.5 because ephedrine alkaloids exhibit higher chemical stability in the protonated form and because Houttuynia cordata flavonoids are less prone to oxidative browning at acidic pH. Batch-to-batch variance in the herbal raw material requires adjustment of the suspending agent concentration by 0.05 g/100 mL increments based on a 6 h settling test; a final drench that shows visible phase separation before the end of the labeled shelf life fails the specification for uniformity of delivered dose. Total aerobic microbial count is controlled below 10² CFU/g according to ISO 4833-1:2013, and a larger settleometer drift above 1.0 mm after 24 h is considered unsuitable for pass-through oral syringes under field conditions.
Competitive Mahuang Yuxingcao Powder Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8618963613625 or mail to sales10@sinochem-nanjing.com.
We will respond to you as soon as possible.
Tel: +8618963613625
Email: sales10@sinochem-nanjing.com
Flexible payment, competitive price, premium service - Inquire now!
For veterinary formulation development, Mahuang Yuxingcao Powder is supplied as a botanical active pharmaceutical ingredient prepared from the dried aerial parts of Ephedra sinica Stapf and Houttuynia cordata Thunb, with the full botanical composition controlled by the current Chinese Veterinary Pharmacopoeia monograph. The material is designated in procurement documentation by a supplier-specific item code rather than a universal pharmacopoeial identifier; where a model-style designation is required, it typically encodes the target particle size and dosage-form route, such as an 80-mesh premix grade or a 100-mesh granule grade. The powder is assigned for use in tablets, injections, capsules, powders, granules, premix, and solutions, but the dry botanical powder is directly applicable only to solid oral and feed-based forms. Injections and solutions require a separate extraction, purification, and sterile-fill sequence because the raw powder is not sterile and is not pyrogen-controlled for parenteral administration. Representative particle size targets are D90 150 µm for premix incorporation, D90 75 µm for direct powders and granules, and D90 45 µm for capsule and tablet blending. These values are supplier engineering targets and must be verified by sieve analysis or laser diffraction against the current certificate of analysis.
The specification sheet issued with each batch is structured around compendial botanical powder monographs and is used to confirm fitness for the intended final dosage form. The criteria below represent a harmonized specification framework for a veterinary botanical API; the current Chinese Veterinary Pharmacopoeia monograph for Mahuang Yuxingcao Powder takes precedence over any general table. Because the material is a multi-botanical matrix rather than a single isolated molecule, assay and impurity methods are based on marker-compound chromatography and chromatographic fingerprinting, not on a single peak purity calculation. The laboratory method must be validated according to ICH Q2(R1), and the certificate of analysis should state the marker compound used for assay, the HPLC column chemistry, and the detector wavelength. Loss on drying is routinely measured by USP <731> or Ph. Eur. 2.2.32. Elemental impurities are evaluated by USP <232> and USP <233>. Microbial enumeration follows USP <61> and USP <62>.
Table 1. Representative specification profile for Mahuang Yuxingcao Powder as a veterinary botanical API; compendial monograph limits prevail where stricter.
| Parameter | Method | Typical acceptance criterion |
|---|---|---|
| Appearance | Visual inspection | Yellow-brown to brown powder; no visible foreign matter |
| Identification | TLC/HPLC fingerprint | Positive for ephedrine and Houttuynia marker components |
| Loss on drying | USP <731> / Ph. Eur. 2.2.32 | Not more than 10.0% |
| Total ash | USP <561> / Ph. Eur. 2.4.16 | Not more than 12.0% |
| Acid-insoluble ash | USP <561> | Not more than 5.0% |
| Lead | USP <232>/<233> | Not more than 5 mg/kg |
| Cadmium | USP <232>/<233> | Not more than 1 mg/kg |
| Arsenic | USP <232>/<233> | Not more than 2 mg/kg |
| Mercury | USP <232>/<233> | Not more than 0.2 mg/kg |
| Total aerobic microbial count | USP <61> | Not more than 10⁴ CFU/g |
| Total yeast and mold count | USP <61> | Not more than 10² CFU/g |
| Escherichia coli | USP <62> | Absent in 1 g |
| Salmonella | USP <62> | Absent in 10 g |
| Assay marker, ephedrine hydrochloride | HPLC-UV | Monograph-defined range; report result |
Because dry blending uniformity for low-dose botanical actives is governed by particle size distribution, moisture content, and surface energy, the powder must be characterized before dry mixing. A common failure mode on production lines is segregation when the product is blended with free-flowing granular excipients such as anhydrous lactose or dibasic calcium phosphate dihydrate. The difference between the D90 of the botanical powder and the D90 of the excipient should be controlled within approximately 3:1 to reduce percolation segregation. Blend uniformity is assessed by sampling at 10 locations using a slot thief and determining the marker compound by HPLC. Acceptance for a validated blend is typically a relative standard deviation not greater than 5.0%, consistent with the intent of USP <905> or Ph. Eur. 2.9.40. If the blend fails this limit, the corrective action is usually a geometric pre-dilution step or a change in milling classification rather than a simple extension of blending time, because prolonged blending can increase electrostatic charge and re-segregate fines.
Direct compression of the unmodified powder is generally not feasible because the fibrous botanical matrix has poor flow and high elastic recovery. Wet granulation with a binder solution such as 5% povidone K30 or starch paste is the preferred tablet route. The granulation endpoint is normally reached when granules pass through a 14-mesh screen and retain sufficient moisture for compaction. A fluid bed dryer inlet temperature of 50–60 °C is used to avoid thermal degradation of ephedrine alkaloids. Finished granules intended for tableting should have loss on drying in the range of 2.0–4.0%; granules below 2.0% may cause capping and lamination in a rotary tablet press because the dried botanical fibers lose binding capacity. Tablet disintegration is tested according to USP <701>, with a typical specification of not more than 15 minutes in water at 37 °C. Capsule manufacture uses powders or granules with a flow-enhancing lubricant such as magnesium stearate at 0.5% w/w; the lubricant level is kept low because excess magnesium stearate can retard dissolution of the extracted marker.
For injections and solutions, the dry powder is not directly injectable. The parenteral route requires a validated decoction or hydroalcoholic extraction in a steam-jacketed extractor, followed by chilled centrifugation and sequential membrane filtration through 0.45 µm and 0.22 µm filters. The resulting solution must meet the final product monograph for bacterial endotoxins, sterility, clarity, and pH. Published data for the endotoxin load of crude Mahuang Yuxingcao Powder are limited; therefore, depyrogenation and hold-time studies must be conducted for each extraction batch. The presence of insoluble plant fibers, pigments, and colloidal polysaccharides makes solution filtration more difficult than handling a purified synthetic API. Solution processing should include a cold settling step at 2–8 °C before membrane filtration to reduce filter fouling and improve throughput.
Formulation trials with electrolyte-rich premixes show that the botanical alkaloid fraction is sensitive to strongly acidic or strongly alkaline microenvironments. Ephedrine-type alkaloids are prone to oxidation and racemization when exposed to pH below 3 or above 8.5 in aqueous granulation. Therefore, direct co-granulation with mineral acids or strongly buffered salts should be limited unless the final granule is evaluated for marker loss. Trace mineral premixes containing hygroscopic salts such as magnesium chloride or calcium chloride can raise the local moisture content of the powder and promote clumping and microbial growth. Storage of the blended premix should be controlled below 60% relative humidity and preferably below 25 °C. If the powder is combined with feed-grade carriers that contain free moisture above 12%, the mixture should be used immediately or dried to avoid mold proliferation.
In a high-shear granulation environment, the botanical powder’s fibrous fraction influences granule growth and final granule density. When the powder is processed in a high-shear granulator with an impeller speed of 300–600 rpm and a chopper speed up to 1500 rpm, granule size increases quickly once the binder is added. Over-wetting leads to large, hard granules that may pass visual inspection but fail disintegration because the compressed tablet forms a poorly soluble waxy or fibrous matrix. A safer process uses a medium impeller speed and staged binder addition, with endpoint determined by torque or power consumption rather than time alone. The target granule size for tableting is often D50 between 120 µm and 250 µm. Granules outside this band can be milled and recompacted, but repeated milling increases fine generation and lowers yield.
The intended use of Mahuang Yuxingcao Powder as a veterinary API differs from synthetic single-entity drugs in several process and control dimensions. A synthetic API such as doxycycline hyclate or tilmicosin phosphate is defined by a single molecular entity with a tight assay range, typically 98.0–102.0%, and a limited set of specified impurities. In contrast, the botanical powder is a multi-component matrix controlled by marker assay, chromatographic fingerprint, and total extractable profile. Batch-to-batch variance arises from botanical origin, harvest year, drying method, and milling conditions. This does not preclude use as an API, but it requires a broader specification and more thorough excipient compatibility testing. Compared with a single-herb ephedra powder, the composite with Houttuynia cordata adds flavonoid and volatile fractions that modify solubility, extraction behavior, and the chromatographic fingerprint. Compared with a standardized dry extract, the crude powder retains natural insoluble fibers and a slower extraction profile, which is advantageous for oral powder and premix products but less suitable for clear solution manufacturing.
Table 2. Comparative processing profile of Mahuang Yuxingcao Powder versus common alternative APIs.
| Parameter | Mahuang Yuxingcao Powder API | Synthetic single-entity veterinary API | Standardized single-herb ephedra extract |
|---|---|---|---|
| Assay basis | Multi-marker HPLC fingerprint | Single analyte, 98.0–102.0% | Ephedrine alkaloid marker |
| Typical particle size | D90 45–150 µm | D90 20–80 µm, depending on milling | D90 50–200 µm, depending on source |
| Solubility in water | Partially soluble; requires decoction for injectable solutions | API-dependent; many are freely soluble salts | Partially soluble; extract solution requires filtration |
| Endotoxin control | Not pyrogen-controlled as dry powder; oral use only unless processed | Can be depyrogenated and sterilized for parenterals | Extract solution must be filtered and tested |
| Batch variability | Botanical origin, harvest, and drying dependent | Controlled by synthesis and purification | Botanical origin and extraction dependent |
| Microbial burden | Requires compendial microbial limits for oral dosage | Generally low for synthetic materials | Moderate; extract processing may reduce count |
For aqueous solution manufacturing, the botanical powder is subjected to a multi-stage extraction sequence in a steam-jacketed extractor. The extract is concentrated under reduced pressure at a temperature not exceeding 65 °C to avoid thermal loss of ephedrine marker. After concentration, the liquid is clarified by refrigerated centrifugation at 2–8 °C and then passed through a plate-and-frame filter with 0.45 µm media, followed by a sterile-grade 0.22 µm membrane. Published data for the specific injection-grade decoction hold time at 25 °C are limited; therefore, hold-time studies should be conducted under the intended manufacturing schedule and storage conditions. The filtered solution should be filled into depyrogenated containers under aseptic conditions and subjected to final sterility testing according to the registered product monograph. If the solution is intended as an oral drench rather than a parenteral, microbial limits follow the less stringent oral liquid requirements, but the same filtration and preservation strategy must be defined during process qualification.